期刊
FRONTIERS IN PHARMACOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.906608
关键词
BK channel; pancreatic duct; pancreatic duct adenocarcinoma (PDAC); BK activators; cancer; NS11021; NS19504; BMS191011
资金
- Fondazione AIRC per la Ricerca sul Cancro [IG 21558]
- Italian Research Ministry [PRIN 20174TB8KW]
BK is a potassium channel with allosteric regulation by Ca2+ binding and voltage. It plays various physiological roles in different tissues, including regulation of pancreatic juice composition. Studies suggest a potential pharmacological role of BK in PDAC, but caution is needed due to potential misleading effects on cancer cells.
BK (KCa 1.1, Slo-1) is a K+ channel characterized by an allosteric regulation of the gating mechanism by Ca2+ binding and voltage, and a high unitary conductance. The channel is expressed in many different tissues, where it is involved in the regulation or the fine-tuning of many physiological processes. Among other organs, BK is expressed in the pancreatic duct, a part of the gland important for the correct ionic composition of the pancreatic juice. Unfortunately, the pancreatic duct is also the site where one of the deadliest cancer types, the pancreatic duct adenocarcinoma (PDAC), develops. In the past years, it has been reported that continuous exposure of cancer cells to BK openers can have a significant impact on cell viability as well as on the ability to proliferate and migrate. Here, we first summarize the main BK channel properties and its roles in pancreatic duct physiology. Then we focus on the potential role of BK as a pharmacological target in PDAC. Moreover, we discuss how results obtained when employing BK activators on cancer cells can, in some cases, be misleading.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据